Stock screener

KYMR

Conviction 76HealthcareScan · Thu, Sep 24, 2026

Kymera Therapeutics, Inc. (KYMR) closed at $115.82 (+0.30%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 49, RS Rating 95, -9.0% from its 52-week high, +59.2% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

KYMR$115.82+0.30%
ResistanceSupportVol 14Insider sell
63 bars
14
28
Vol MA14 854.9K
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Kymera Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.kymeratx.com ↗
Price115.82
Change+0.30%
Gap-0.77%
Rel volume2.74×
Avg volume789.42K
Avg $ vol92.45M
SMA 20117.24
SMA 50114.70
SMA 20092.38
Price vs 50+0.98%
Price vs 200+25.37%
MA stackbullish
50/200 cross—
Supertrendup · 110.04
RSI (14)49
MACD hist-0.29
MACD crossbear · 1d
Stoch %K / %D44 / 58
ADX (14)16
+DI / −DI21 / 23
RSI divergence—
MACD divergence—
ATR %4.45%
ADR %4.23%
52w high127.31
52w low52.50
From 52w high-9.03%
Above 52w low+120.61%
New 52w highNo
SqueezeOn · 2d
Bollinger width6.88%
%B0.32
Donchian pos37.43%
Donchian high125.07
Donchian low110.29
AVWAP (52w high)114.58
vs AVWAP high+1.08%
AVWAP (52w low)87.55
vs AVWAP low+32.30%
OBV trendDown
Chaikin MF (20)-0.00
Today vs 20d2.74×
Avg vol (14d)854.9K
Avg vol (20d)789.42K
Avg $ vol (20d)92.45M
Market cap9.63B
RS Rating95 / 99
RS 3m (vs SPY)-5.04%
RS 6m (vs SPY)+29.92%
RS line new highNo
Trend template7/8
Technical rank76.0
1 week-2.25%
1 month-8.54%
3 months-0.55%
6 months+46.74%
1 year+127.68%
YTD+59.18%
P/E-30.93
P/B6.38
P/S245.61
P/FCF-41.10
EPS-3.69
Div yield—
ROE-20.63%
ROA-18.92%
Debt/Eq—
Current10.34
EV/EBITDA-27.87
Gross margin—
Net margin-794.04%
Rev growth-16.70%
EPS growth-39.08%
Price target140.78
Target upside21.55%
Analyst ratingBuy
Institutional124.91%
Ent. value9.51B
Revenue65M
Net income-61.21M
Gross profit—
Free cash flow-234.34M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out82.26M
Employees253
ListedFri, Aug 21, 2020
Free float24.21M
Float %77.2%
Short interest10.37M
Days to cover16.8d
Short volume66.5%
Squeeze score98 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.62 vs −$0.64
Last surprise+3.1% beat
Setup gradeA
Conviction76 / 100
Pattern quality—
Tech rank76.0 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance127.61
Support104.91
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KYMR

All disclosures →
No recent disclosed trades by Congress in KYMR. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KYMR · open-market 5 sells

InsiderSideShares
Rooney Terence
Chief Medical Officer · Stock Option (Right to Buy) · 2026-07-27
Grant76K
Rooney Terence
Chief Medical Officer · Common Stock · 2026-07-27
Grant38K
Mainolfi Nello
Chief Executive Officer · Common Stock · 2026-07-07
Exercise50K
Mainolfi Nello
Chief Executive Officer · Common Stock · 2026-07-07
Sell50K
Mainolfi Nello
Chief Executive Officer · Stock Option (Right to Buy) · 2026-07-07
Exercise45.56K
Mainolfi Nello
Chief Executive Officer · Stock Option (Right to Buy) · 2026-07-07
Exercise4.44K
Booth Bruce
Director · Common Stock · 2026-06-29
Sell157
Booth Bruce
Director · Common Stock · 2026-06-29
Sell7.83K
Booth Bruce
Director · Common Stock · 2026-06-29
Sell7.6K
Booth Bruce
Director · Common Stock · 2026-06-29
Sell907

SEC filings

EDGAR filings in KYMR · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.